(MedPage Today) — The FDA approved milsaperidone (Bysanti) tablets as first-line therapy for adults with schizophrenia and manic or mixed episodes related to bipolar I disorder, Vanda Pharmaceuticals announced on Friday.
Milsaperidone is an active…
Source link : https://www.medpagetoday.com/psychiatry/bipolardisorder/120004
Author :
Publish date : 2026-02-23 20:49:00
Copyright for syndicated content belongs to the linked Source.
